A Phase 1 Study of Nexvax2 Administered Subcutaneously After a Screening Gluten Food Challenge That Compares Relative Bioavailability With Intradermal Administration in Non-homozygous HLA-DQ2.5+ Adults With Celiac Disease
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2018
At a glance
- Drugs HLA DQ2 peptide vaccine (Primary) ; HLA DQ2 peptide vaccine (Primary)
- Indications Coeliac disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ImmusanT
- 19 Sep 2018 Status changed from active, no longer recruiting to completed.
- 26 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2018 New trial record